2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1740

Impairment of Quality of Life in Patients with Antiphospholipid Syndrome
Abstract Number: 857

Impairment of the Inhibitory PD-1-PD-L1 Axis in Giant Cell Arteritis (GCA)
Abstract Number: 2406

Implementation of a Pilot Nutrition Education Intervention for Culturally Diverse Teens with Lupus and Their Families in Hospital for Special Surgery’s Charla De Lupus /Lupus Chat® Teen and Parent Support Group
Abstract Number: 1293

Importance of Steady-State Trough Concentrations After Intravenous Golimumab with Concomitant Methotrexate in Subjects with Active Rheumatoid Arthritis
Abstract Number: 1236

Important Prognostic Factor in Rheumatoid Arthritis Patients with Interstitial Lung Disease Is Not Usual Interstitial Pneumonia Pattern but Interstitial Lung Disease Extent On Chest High-Resolution Computed Tomography
Abstract Number: 367

Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis
Abstract Number: 359

Improved Radiological Outcome of Rheumatoid Arthritis: Early Treatment with methotrexate might be a key Prognostic Factor
Abstract Number: 1934

Improvement in Cryoglobulin Detection Employing a Temperature Controlled Sample Transporter
Abstract Number: 1152

Improvement in Health-Related Quality of Life for Children with Juvenile Ideopathic Arthritis After Start of Treatment with Etanercept
Abstract Number: 1353

Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Nonradiographic Axial Spa: Wk-52 Results From Ability-1
Abstract Number: 2225

Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)
Abstract Number: 365

Improvement of Health-Related Quality of Life in RA Patients Treated with Biologics – One-Year Follow-up Data of the German Biologics Register Rabbit
Abstract Number: 1298

Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
Abstract Number: 147

Improvements in Long-Term Health-Related Quality of Life in Chronic Gout Patients Refractory to Conventional Therapies Treated with Pegloticase: Results From Responder Cohort
Abstract Number: 2041

Improving Access and Patient Education in Rheumatology: the Gout Shared Medical Appointment; a Quality Improvement Initiative

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].